1r81: Difference between revisions

No edit summary
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
Human ABO(H) blood group glycosyltransferases GTA and GTB catalyze the, final monosaccharide addition in the biosynthesis of the human A and B, blood group antigens. GTA and GTB utilize a common acceptor, the H antigen, disaccharide alpha-l-Fucp-(1-->2)-beta-d-Galp-OR, but different donors, where GTA transfers GalNAc from UDP-GalNAc and GTB transfers Gal from, UDP-Gal. GTA and GTB are two of the most homologous enzymes known to, transfer different donors and differ in only 4 amino acid residues, but, one in particular (Leu/Met-266) has been shown to dominate the selection, between donor sugars. The structures of the A and B glycosyltransferases, have been determined to high resolution in complex with two inhibitory, acceptor analogs alpha-l-Fucp(1-->2)-beta-d-(3-deoxy)-Galp-OR and, alpha-l-Fucp-(1-->2)-beta-d-(3-amino)-Galp-OR, in which the 3-hydroxyl, moiety of the Gal ring has been replaced by hydrogen or an amino group, respectively. Remarkably, although the 3-deoxy inhibitor occupies the same, conformation and position observed for the native H antigen in GTA and, GTB, the 3-amino analog is recognized differently by the two enzymes. The, 3-amino substitution introduces a novel intramolecular hydrogen bond, between O2' on Fuc and N3' on Gal, which alters the minimum-energy, conformation of the inhibitor. In the absence of UDP, the 3-amino analog, can be accommodated by either GTA or GTB with the l-Fuc residue partially, occupying the vacant UDP binding site. However, in the presence of UDP, the analog is forced to abandon the intramolecular hydrogen bond, and the, l-Fuc residue is shifted to a less ordered conformation. Further, the, residue Leu/Met-266 that was thought important only in distinguishing, between donor substrates is observed to interact differently with the, 3-amino acceptor analog in GTA and GTB. These observations explain why the, 3-deoxy analog acts as a competitive inhibitor of the glycosyltransferase, reaction, whereas the 3-amino analog displays complex modes of inhibition.
Human ABO(H) blood group glycosyltransferases GTA and GTB catalyze the final monosaccharide addition in the biosynthesis of the human A and B blood group antigens. GTA and GTB utilize a common acceptor, the H antigen disaccharide alpha-l-Fucp-(1-->2)-beta-d-Galp-OR, but different donors, where GTA transfers GalNAc from UDP-GalNAc and GTB transfers Gal from UDP-Gal. GTA and GTB are two of the most homologous enzymes known to transfer different donors and differ in only 4 amino acid residues, but one in particular (Leu/Met-266) has been shown to dominate the selection between donor sugars. The structures of the A and B glycosyltransferases have been determined to high resolution in complex with two inhibitory acceptor analogs alpha-l-Fucp(1-->2)-beta-d-(3-deoxy)-Galp-OR and alpha-l-Fucp-(1-->2)-beta-d-(3-amino)-Galp-OR, in which the 3-hydroxyl moiety of the Gal ring has been replaced by hydrogen or an amino group, respectively. Remarkably, although the 3-deoxy inhibitor occupies the same conformation and position observed for the native H antigen in GTA and GTB, the 3-amino analog is recognized differently by the two enzymes. The 3-amino substitution introduces a novel intramolecular hydrogen bond between O2' on Fuc and N3' on Gal, which alters the minimum-energy conformation of the inhibitor. In the absence of UDP, the 3-amino analog can be accommodated by either GTA or GTB with the l-Fuc residue partially occupying the vacant UDP binding site. However, in the presence of UDP, the analog is forced to abandon the intramolecular hydrogen bond, and the l-Fuc residue is shifted to a less ordered conformation. Further, the residue Leu/Met-266 that was thought important only in distinguishing between donor substrates is observed to interact differently with the 3-amino acceptor analog in GTA and GTB. These observations explain why the 3-deoxy analog acts as a competitive inhibitor of the glycosyltransferase reaction, whereas the 3-amino analog displays complex modes of inhibition.


==Disease==
==Disease==
Line 17: Line 17:
[[Category: Homo sapiens]]
[[Category: Homo sapiens]]
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Borisova, S.N.]]
[[Category: Borisova, S N.]]
[[Category: Cai, Y.]]
[[Category: Cai, Y.]]
[[Category: Evans, S.V.]]
[[Category: Evans, S V.]]
[[Category: Leinala, E.K.]]
[[Category: Leinala, E K.]]
[[Category: Nguyen, H.P.]]
[[Category: Nguyen, H P.]]
[[Category: Palcic, M.M.]]
[[Category: Palcic, M M.]]
[[Category: Seto, N.O.L.]]
[[Category: Seto, N O.L.]]
[[Category: HG]]
[[Category: HG]]
[[Category: UD2]]
[[Category: UD2]]
Line 31: Line 31:
[[Category: transmembrane]]
[[Category: transmembrane]]


''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri Feb 15 16:47:41 2008''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 14:48:04 2008''

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA